Phibro Animal Health wrapped up its three-year enterprise transformation program, Phibro Forward, on June 30, and the operational changes are now embedded in the company's performance, the company says. Based on Phibro's fiscal 2027 outlook, nearly one out of every five dollars of adjusted earnings before interest, taxes, depreciation and amortization can be traced directly to Phibro Forward initiatives, the company says. The program focused on improving accountability, sharpening execution and strengthening operations. Adjusted Ebitda climbed 39% to $255 million in fiscal 2026, and the company expects modest continued growth with fiscal 2027 guidance of $258 million to $268 million.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.